Low Frequency Of The ERG Oncogene Alterations In Prostate Cancer Patients From India

Journal of Cancer

Volumn 4, Issue 6, 2013, Pages 468-472

  Rawal, Sudhir ^a   Young, Denise ^b   Williams, Molly ^b,c   Colombo, Monica ^b,c   Krishnappa, Raghunath ^d   Petrovics, Gyorgy ^b   McLeod, David G ^b,c   Srivastava, Shiv ^b   Sesterhenn, Isabell A ^e  

^a RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d HCG Bangalore Institute of Oncology   (India)

^e JOINT PATHOLOGY CENTER   (United States)

Author keywords

ERG oncogene; India.; Prostate cancer

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER;

EID: 84882931591     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6568     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 ;63(1):11-30.
2. [Internet] Ferlay JSH, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10. http://globocan.iarc.fr.
3. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-864.
4. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005;41(6):834-845.
5. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15(14):4706-4711.
6. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69(4):1400-1406.
7. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Modern Pathology. 2007;20(4):467-473.
8. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-8341.
9. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol. 2007;60(11):1238-1243.
10. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Modern Pathology. 2007;20(9):921-928.
11. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern Pathology. 2008;21(12):1451-1460.
12. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310: 644-648.
13. Petrovics G, Liu A, Shaheduzzaman S et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24: 3847-3852.
14. Rubin MA, Maher CA and Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clinic Oncol. 2011;29: 3659-3668.
15. Sreenath TL, Dobi A, Petrovics G et al. Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinogen. 2011;10: 37.
16. Dobi A, Sreenath T, Srivastava S. Androgen dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and Clinical Implications. In: Wang Z, ed. Androgen-Responsive Genes in Prostate Cancer. New York, USA: Springer. 2013.
17. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008;27: 5348-5353.
18. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell, 2011;19: 664-78.
19. Shao L, Tekedereli I, Wang J, et al. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012;18: 6648-57.
20. Rosen P, Pfister D, Young D, et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology. 2012 Oct;80(4):749-53.
21. Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. The Prostate. 2011;71(5):489-497.
22. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24(23):3847-852.
23. Miyagi Y, Sasaki T, Fujinami K, et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Modern Pathology. 2010;23(11):1492-1498.
24. Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010;70(13):5207-5212.
25. Furusato B, van Leenders GJ, Trapman J et al. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int. 2011;61: 409-14.
26. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37.
27. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-41.
28. Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. J Urol. 2009;182(6):2938-2943.
29. Srivastava DS, Mandhani A, Mittal B, Mittal RD. Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int. 2005;95(1):170-173.
30. Gsur A, Haidinger G, Hinteregger S, et al. Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer. 2001;95(3):152-155.
31. Murata M, Shiraishi T, Fukutome K, et al. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol. 1998;28(11):657-660.
32. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB. Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(4 Pt 1):283-287.
33. Steinhoff C, Franke KH, Golka K, et al. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol. 2000;74(9):521-526.
34. Tan YC, Zeigler-Johnson C, Mittal RD, et al. Common 8q24 sequence variations are associated with Asian Indian advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2431-5.